BioLineRx (BLRX) to Commence BL-8020 Phase I/II in Europe During Q113
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioLineRx (BLRX) Pops Higher on BL-8020 Phase I/II Plans
October 16, 2012 7:40 AM EDTBioLineRx (Nasdaq: BLRX) shares are ripping in pre-market trading Tuesday following an update on BL-8020. Shares are 11 percent higher ahead of the bell.
According to a release out earlier, "[BioLineRx] has successfully completed the pre-clinical development of BL-8020, an orally available,... More
